Damora Therapeutics, Inc. (DMRA)
Nasdaq: DMRA · CIK 0001800315 · United States
Every official Damora Therapeutics, Inc. filing in one place: annual reports, quarterly results, current reports,
proxy statements, shareholding and announcements, straight from the regulator. Free to search.
Open DMRA filings
Damora Therapeutics, Inc. documents
- Damora Therapeutics, Inc. 10-K 2026DMRA 10-K 2026: annual report for fiscal 2026
- Damora Therapeutics, Inc. 10-K 2025DMRA 10-K 2025: annual report for fiscal 2025
- Damora Therapeutics, Inc. 10-K 2024DMRA 10-K 2024: annual report for fiscal 2024
- Damora Therapeutics, Inc. 10-K 2023DMRA 10-K 2023: annual report for fiscal 2023
- Damora Therapeutics, Inc. 10-K 2022DMRA 10-K 2022: annual report for fiscal 2022
- Damora Therapeutics, Inc. 10-Q 2026DMRA 10-Q 2026: quarterly report for fiscal 2026
- Damora Therapeutics, Inc. 10-Q 2025DMRA 10-Q 2025: quarterly report for fiscal 2025
- Damora Therapeutics, Inc. 10-Q 2024DMRA 10-Q 2024: quarterly report for fiscal 2024
- Damora Therapeutics, Inc. 10-Q 2023DMRA 10-Q 2023: quarterly report for fiscal 2023
- Damora Therapeutics, Inc. 10-Q 2022DMRA 10-Q 2022: quarterly report for fiscal 2022
- Damora Therapeutics, Inc. 8-K 2026DMRA 8-K 2026: current report for fiscal 2026
- Damora Therapeutics, Inc. 8-K 2025DMRA 8-K 2025: current report for fiscal 2025
- Damora Therapeutics, Inc. 8-K 2024DMRA 8-K 2024: current report for fiscal 2024
- Damora Therapeutics, Inc. 8-K 2023DMRA 8-K 2023: current report for fiscal 2023
- Damora Therapeutics, Inc. 8-K 2022DMRA 8-K 2022: current report for fiscal 2022
- Damora Therapeutics, Inc. DEF 14A 2026DMRA DEF 14A 2026: proxy statement for fiscal 2026
- Damora Therapeutics, Inc. DEF 14A 2025DMRA DEF 14A 2025: proxy statement for fiscal 2025
- Damora Therapeutics, Inc. DEF 14A 2024DMRA DEF 14A 2024: proxy statement for fiscal 2024
- Damora Therapeutics, Inc. DEF 14A 2023DMRA DEF 14A 2023: proxy statement for fiscal 2023
- Damora Therapeutics, Inc. DEF 14A 2022DMRA DEF 14A 2022: proxy statement for fiscal 2022
- Damora Therapeutics, Inc. Form 4 2026DMRA Form 4 2026: insider trading filing for fiscal 2026
- Damora Therapeutics, Inc. Form 4 2025DMRA Form 4 2025: insider trading filing for fiscal 2025
- Damora Therapeutics, Inc. Form 4 2024DMRA Form 4 2024: insider trading filing for fiscal 2024
- Damora Therapeutics, Inc. Form 4 2023DMRA Form 4 2023: insider trading filing for fiscal 2023
- Damora Therapeutics, Inc. Form 4 2022DMRA Form 4 2022: insider trading filing for fiscal 2022
- Damora Therapeutics, Inc. S-1 2026DMRA S-1 2026: registration statement for fiscal 2026
- Damora Therapeutics, Inc. S-1 2025DMRA S-1 2025: registration statement for fiscal 2025
- Damora Therapeutics, Inc. S-1 2024DMRA S-1 2024: registration statement for fiscal 2024
- Damora Therapeutics, Inc. S-1 2023DMRA S-1 2023: registration statement for fiscal 2023
- Damora Therapeutics, Inc. S-1 2022DMRA S-1 2022: registration statement for fiscal 2022
- Damora Therapeutics, Inc. 13F 2026DMRA 13F 2026: institutional holdings for fiscal 2026
- Damora Therapeutics, Inc. 13F 2025DMRA 13F 2025: institutional holdings for fiscal 2025
- Damora Therapeutics, Inc. 13F 2024DMRA 13F 2024: institutional holdings for fiscal 2024
- Damora Therapeutics, Inc. 13F 2023DMRA 13F 2023: institutional holdings for fiscal 2023
- Damora Therapeutics, Inc. 13F 2022DMRA 13F 2022: institutional holdings for fiscal 2022
More companies